Skip to main content
Fig. 1 | BMC Gastroenterology

Fig. 1

From: Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study)

Fig. 1

Study scheme. HFS hand foot syndrome. Topical hydrocortisone butyrate 0.1% and standard moisturizing therapy are applied to the hands and feet daily in the morning and evening, started on day 1 and continued until the end of adjuvant chemotherapy. To keep patients’ self-adherence, all patients received standard self-care education at the start of the chemotherapy, and is confirmed the amount of topical hydrocortisone butyrate 0.1% used regularly by clinical pharmacists. Clinical pharmacists regularly educate the patients to improve self-adherence to intervention protocols

Back to article page